1. Home
  2. CBIO vs GLSI Comparison

CBIO vs GLSI Comparison

Compare CBIO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$19.37

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$27.10

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
GLSI
Founded
2003
2006
Country
United States
United States
Employees
44
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.8M
372.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CBIO
GLSI
Price
$19.37
$27.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
1
Target Price
$26.67
$50.00
AVG Volume (30 Days)
247.8K
112.6K
Earning Date
05-23-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$279.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.72
$7.78
52 Week High
$20.68
$34.10

Technical Indicators

Market Signals
Indicator
CBIO
GLSI
Relative Strength Index (RSI) 68.18 56.21
Support Level $10.89 $21.20
Resistance Level $20.58 $30.02
Average True Range (ATR) 1.77 1.88
MACD 0.12 0.42
Stochastic Oscillator 83.31 86.22

Price Performance

Historical Comparison
CBIO
GLSI

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: